Cupid Ltd Q4 FY2023 Concall Summary

Key Takeaways

• Earnings surge on stable costs: PAT nearly doubled QoQ and rose 82% for the full year, driven by lower input costs and better operating efficiency.
• Founder exit talks dominate the narrative: The promoter is negotiating a full exit at a minimum INR300 per share, with a decision expected within six months; the outcome will determine management, strategy and capital allocation.
• US FDA entry opens a monopoly market: The FDA encouraged Cupid’s female condom application, seeking a competitor to a product that has held a monopoly since 2009; approval is targeted within 15 months.
• IVD is a high-stakes, long-dated bet: Management targets INR100 crores in IVD revenue by FY26, but the division lost INR1.4 crores on sales of just INR40 lakhs this year and cannot yet bid on large tenders.
• What to watch next quarter: Whether the stake sale crystallizes, the South Africa tender outcome in June, and any progress on the US FDA supplementary study.

The Promoter Exit

• Full stake sale on the table: Promoter Omprakash Garg and his wife hold 45% and plan to exit fully; negotiations are ongoing with an independent investor who is not a condom manufacturer.
• Valuation floor set: Management expects a minimum of INR300 per share, though it declined to disclose the valuation method or multiple, saying "everybody has their own method."
• Succession tied to the deal: If the investor proceeds, they will bring their own CEO and CFO, with Garg possibly staying in an advisory role for 2–3 years. If no deal happens, the family will continue running the business with the existing COO and management team.
• Capital allocation in limbo: A share buyback is "constantly evaluating" but deferred until cash flow needs for capacity expansion and IVD working capital are clearer, a decision expected in the next six months alongside the stake sale outcome.

Garg: "We have provided all the information the investors were looking for, and now they are in the process of organizing their strategy and funding for this deal. So the ball is in their court and very difficult for us to be more precise on what their thinking is."

US FDA Opportunity

• A monopoly market since 2009: Only one female condom product is currently sold in the US, and the FDA explicitly told Cupid it wants a competitive product. The agency recommended a supplementary study with a specific demographic mix: 60% white, 30% black, 10% Asian Indian participants in South Africa.
• Timeline targets 15 months: Management plans to submit the new application nine months from June, with FDA approval expected 3–6 months after submission, putting permission around this time next year.
• First-year economics: Cupid projects roughly \$1 million (INR8 crores) in first-year US sales at a 50% profit margin, yielding about INR4 crores in net profit after marketing costs.
• Study restart after COVID delay: The original South Africa study began in 2020, stopped for 2.5 years during the pandemic, and resumed only after the report was submitted late last year, which triggered the FDA’s evaluation and supplementary request.

Garg: "In general, we had a positive response from US FDA that at least one other manufacturers like Cupid is trying to get into this field. As you know, currently, there is only one product, which has had monopoly since 2009. So FDA would also like to see a competitive product."

IVD: The INR100 Crore Ambition

• Current reality is tiny and loss-making: The IVD division generated sales of only INR40 lakhs in FY23, down from INR3.7 crores the prior year, and posted a loss of INR1.4 crores. The business was delayed 2.5 years by COVID.
• The tender qualification trap: Large global tenders require three years of operating experience, which Cupid will not complete until November 2024, locking it out of the biggest opportunities for now. WHO approval is expected around December 2024.
• Five products, better margins: The focus is on HIV, Dengue, Malaria, Syphilis and pregnancy test kits. The first four face less competition and carry margins at least 20 percentage points higher than condoms.
• The ramp-up math: Management forecasts INR2.5 crores in IVD sales for FY24, breakeven once sales cross INR5 crores, and a leap to INR50–100 crores starting in FY26 after WHO approval and the three-year qualification unlock worldwide tenders.
• An analyst questioned the viability of the entire IVD project given weak demand and overcapacity; management did not directly address the concern, instead describing the product advantages.

Garg: "I see FY '26 target could be as high as INR100 crores from IVD alone."

Core Business & Order Book

• Export-heavy, customer-concentrated: Exports were 94% of revenue, with top customer UNFPA alone accounting for about INR57 crores in purchases during FY23. Six or seven other customers have been ordering for many years.
• Order book and capacity: The order book stood at INR177 crores as of April 1. Current capacity is 56 crore pieces per year, running at 94% utilization, and management is evaluating a 12–15% expansion costing INR12–15 crores over 12–15 months, but only if it sees continuous multi-year orders.
• Product mix stable: Male condoms contribute 75% of sales, female condoms 23%, and other products 2%. Female condom demand is increasing, with India’s Ministry of Health contemplating an additional tender.
• Lubricant quality issue: UNFPA cancelled orders for water-based lubricant jelly after quality parameters deteriorated during transit or storage. Management expects the issue to be resolved in 3–4 months and forecasts lubricant sales of a maximum INR10 crores in FY24, with a major expansion to INR30 crores in FY25.
• Input cost picture: Most raw material costs are stable or down 5–7%, except natural rubber latex, which rose 6% versus last year due to seasonal monsoon timing in Kerala; management believes this is temporary and expects prices to normalize after rains start in early June.

Garg: "We want to make sure that when we do decide to expand the capacity that we are likely to get the orders continuously for many years to come."

Capital Allocation & Shareholder Returns

• Record dividend, but questions on pace: The board declared a final dividend of INR3 per share, taking the full-year total to INR5, the highest in 30 years. An analyst noted the increase from INR4.5 to INR5 is small relative to 80% profit growth and INR100 crores in cash; management pointed to the buyback evaluation and hoped dividends would improve over time.
• Buyback weighed against other uses: A share buyback is under serious consideration but competes with two other priorities: capex for capacity expansion and working capital for the IVD division. A final call is expected in the next few months.
• Cash returns under review: The company holds significant cash earning roughly 7% in fixed deposits and plans to engage a financial consultant to improve return on investment.
• Inventory discipline: Cupid holds only two weeks of production inventory, issuing one truckload of 175 drums at a time, which limits working capital exposure to raw material price swings.

Guidance & Commitments

Key Metrics